Novo Nordisk Pharmaceutical
Our first US manufacturing facility for diabetes and obesity medicines was established in Clayton, NC in 1993. The facility has expanded rapidly to meet the increasing demand for our products, both locally and globally. We are now investing $2 billion in a new active pharmaceutical ingredient production facility in Clayton, and, we are opening a new tableting and packaging facility in Durham, NC to support an innovative new diabetes treatment. See more on our Who We Are: Clayton and Durham page.